USC/Norris oncologists test new front-line therapy for pancreatic cancer
USC/Norris Comprehensive Cancer Center oncologists are testing the effectiveness of a new drug against pancreatic cancer that targets the cancer from two directions.
In their National Cancer Institute-sponsored phase II clinical trial, researchers are evaluating how well BAY 43-9006 works alone and paired with gemcitabine, todays standard chemotherapy for pancreatic cancer. Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of USC, is principal investigator on the trial, which ultimately aims to add much-needed options to medicines sparse arsenal against pancreatic cancer. Cancer of the pancreas causes about 27,000 deaths each year in the United States alone. "Pancreatic cancer is a major health problem, because we do not yet have highly effective ways to deal with it," says Lenz, director of the gastrointestinal oncology program at USC/Norris. "The cancer is difficult to diagnose early, when it is most treatable, and can be aggressive. Because of the lack of effective systemic therapies, only 1 percent to 4 percent of patients will be alive five years after diagnosis."
But Lenz hopes that targeted medications such as BAY43-9006 will become part of first-line treatment and help patients respond better to chemotherapies.
In this study, researchers will recruit 90 patients with metastatic pancreatic carcinoma. Half of the patients will take a BAY 43-9006 pill twice daily for four weeks, while the other half will both take the pills and receive weekly infusions of gemcitabine for three weeks at a time. Oncologists will evaluate how well tumors respond to the drugs, as well as monitor for side effects. Patients whose cancers progress when taking the new drug alone will be switched to the gemcitabine group.
Unlike traditional chemotherapies, which kill fast-growing cells (even some non-cancerous ones), targeted drugs such as BAY 43-9006 focus exclusively on a few targets specific to cancer cells. In this case, the compound aims to work in two ways: by directly inhibiting critical growth pathways of the cancer cells (even potentially killing the cells), while also attacking the blood vessels needed to nourish the tumor, Lenz says.
BAY 43-9006s first strategy is to disrupt cell signaling in what scientists call the Ras gene pathway. The Ras oncogene drives cell division and is critical to many cancers development; moreover, mutations in the Ras gene occur in 90 percent of pancreatic cancers. By throwing a roadblock in the Ras signaling pathway, BAY 43-9006 attempts to keep cancer cells from proliferating. "This compound also has anti-angiogenic activity," says Lenz. Angiogenesis is a process by which growing tumors recruit new blood vessels to keep them nourished. BAY 43-9006 is thought to inhibit angiogenesis by interfering with vascular endothelial growth factor (VEGF) receptors on blood vessel cells, as well as platelet-derived growth factor (PDGF) receptors, which are found on special cells that provide the external structure for blood vessels.
Encouraging results have already been reported from a phase II trial of the compound in renal cell carcinoma, or kidney cancer, and a phase I/II trial for the treatment of metastatic melanoma.
Sarah Huoh | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...